16007/34347US=22 / Urologia
Rini BI. Additional tyrosine kinase inhibitors in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 189-93. ISBN 978-1-58829-737-2.

INIBIDORES VEGF; TKI; PTK787; AZD2171; ZK222584; INIBIDOR DE TIROSINA CINASE; PAZOPANIB

16008/34347US=22 / Urologia
Ramakrishnan V, Bhaskar V, Fox M, Wilson K, Cheville JC, Finck BA. Integrin &*945;5&*946;1 as a noveltherapeutic target in renal cancer. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 195-209. ISBN 978-1-58829-737-2.

INTEGRINAS NA ANGIOGENESE; TERAPIA ANTI-ANGIOGENICA; CANCER RENAL &*945;5&*946;1; VOLOCIXIMAB

16009/34347US=22 / Urologia
Shuch B, Belldegrun AS, Figlin RA. Carbonic anhydrase IX: biology and clinical approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 211-29. ISBN 978-1-58829-737-2.

CAIX; CCR CELULA CLARA; INTERLEUCINA-2 RESPOSTA; PROGNOSTICO; G250

16010/34347US=22 / Urologia
Oosterwijk-Wakka JC, Boerman OC, Mulders PFA, Oosterwijk E. Monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma: biological and clinical studies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 231-47. ISBN 978-1-58829-737-2.

ANTICORPO MONOVLONAL; G250; IMUMUNOTHERAPY

16011/34347US=22 / Urologia
Reckamp KL, Figlin RA, Strieter RM. Chemokines in renal cell carcinoma: implications for tumor angiogenesis and metastasis. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 249-65. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; QUIMIOCINAS; ANGIOGENESE; POTENCIAL METASTATICO; TRATAMENTO

16012/34347US=22 / Urologia
Cho D, Mier JW, Atkins MB. PI3K/AKt/mTOR pathway: a growth and proliferation pathway. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 267-85. ISBN 978-1-58829-737-2.

INIBIDORES PI3K; RCC; HIPERATIVACAO DO AKT/PI3K; ATIVIDADE AKT; TEMSIROLIMUS

16013/34347US=22 / Urologia
Jonasch E, Walker CL. EGFR and HER2: relevance in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 287-303. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; ERBB; TERAPIA-ALVO; RESISTENCIA; SINALIZACAO

16014/34347US=22 / Urologia
Garcia JA, Varizi SJA, Ganapathi R. Proteasome-NFkB signaling pathway: relevance in RCC. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 305-20. ISBN 978-1-58829-737-2.

SISTEMA UBIQUITINA-PROTEASSOMA; VIA DE PROTEASSOMA NA RCC; INIBICAO DO PROTEASSOMA

16015/34347US=22 / Urologia
Peruzzi B, Lattouf JB, Bottaro DP. The role of hepatocyte growth factor pathway signaling in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 321-34. ISBN 978-1-58829-737-2.

FATOR DE CRESCIMENTO HEPATOCITO; C-MET; CARCINOMA DE CELULAS RENAIS; MECANISMOS ONCOGENICOS; DESENVOLVIMENTO DROGA CONTRA O CANCER

16016/34347US=22 / Urologia
Mizutani Y, kawauchi A, Bonavida B, Miki T. Smac/DIABLO: a proapoptotic molecular target in renal cell cancer. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 335-46. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; SMAC / DIABLO; PROGNOSTICO; APOPTOSE; CISPLATINA; XIAP; RCC; TRAIL

16017/34347US=22 / Urologia
Kawabe M, Herrem CJ, Finke JH, Storkus WJ. EphA2: a novel target in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 347-66. ISBN 978-1-58829-737-2.

RTK; CD8+ T LINFOCITOS; QUINASE DE TIROSINA RECEPTORA; PROTEASSOMA; TERAPIA COMBINATORIA; COMPLEXO PRINCIPAL DE HISTOCOMPATIBILIDADE

16018/34347US=22 / Urologia
Inman BA, Frigola X, Dong H, Yang JC, Kwon ED. Restoring host antitumoral immunity: how coregulatory molecules are changing the approach to the management of renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 367-403. ISBN 978-1-58829-737-2.

COESTIMULACAO; INIBICAO; IMUNOLOGIA DE TUMORES; IMMUNOEDITING; IMUNOTERAPIA; LINFOCITOS T; CARCINOMA DE CELULAS RENAIS

16019/34347US=22 / Urologia
Shaheen PE, Bukowski RM, Finke JH. The role of gangliosides in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 405-23. ISBN 978-1-58829-737-2.

GANGLIOSIDEOS NA RCC; GLICOESFINGOLIPIDOS; GANGLIOSIDOS E VEGF; GANGLIOSIDEOS COMO ALVOS TERAPEUTICOS

16020/34347US=22 / Urologia
Parton M, Das T, Sa G, Finke J, Eisen T, Tannenbaum C. Tumour necrosis factor - misnomer and therapeutic target. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 425-48. ISBN 978-1-58829-737-2.

FATOR DE NECROSE TUMORAL; CITOCINA; IMUNOMODULACAO; ANGIOGENESE; FATOR DE CRESCIMENTO

16021/34347US=22 / Urologia
Nogueira M, Kim HL. Molecular markers for predicting prognosis of renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 449-71. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; MARCADORES MOLECULARES; PROGNOSTICO

16022/34347US=22 / Urologia
Kadar AK, Wood CG. Adjuvant therapy for renal cell carcinoma: targeted approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 473-95. ISBN 978-1-58829-737-2.

TERAPIA ADJUVANTE; CARCINOMA DE CELULAS RENAIS; DOENCA LOCALMENTE AVANCADA

16023/34347US=9 / Quimioterapia
Cross HS, Nittke T. Selected vitamins: vitamina D. In: Knasmüller S, DeMarini DM, Johnson I, Gerhäuser C. Chemoprevention of cancer and DNA damage by dietary factors. Weinheim: Wiley-VCH, 2009. p. 393-402. ISBN 978-3-527-32058-5.

PREVENCAO DO CANCER; VITAMINA D; SINTESE DA VITAMINA D; PROPRIEDADES FISICO-QUIMICAS; BIODISPONIBILIDADE; METABOLISMO; MECANISMOS PROTETORES; PROCESSAMENTO DE ALIMENTOS; NUTRICAO

16024/34347US=9 / Quimioterapia
Lee HJ, Suh N. Selected vitamins: vitamina E. In: Knasmüller S, DeMarini DM, Johnson I, Gerhäuser C. Chemoprevention of cancer and DNA damage by dietary factors. Weinheim: Wiley-VCH, 2009. p. 402-15. ISBN 978-3-527-32058-5.

VITAMINA E; PROPRIEDADES FISICO-QUIMICAS; BIODISPONIBILIDADE; METABOLISMO; MECANISMOS PROTETORES; DANO OXIDATIVO AO DNA; PROCESSAMENTO DE ALIMENTOS; PREVENCAO DO CANCER

16025/34347US=22 / Cirurgia
Colon GA. Office pratice of plastic surgery. In: Aston SJ, Steinbrech DS, Walden JL. Aesthetic plastic surgery. Philadelphia: Elsevier Saunders, 2009. p. 3-13. ISBN 978-0-7020-3168-7.

CIRURGIA PLASTICA; SERVICO DE CIRURGIA PLASTICA; MARKETING

16026/34347US=22 / Cirurgia
Lambros V. Clinical photography for the aesthetic patient. In: Aston SJ, Steinbrech DS, Walden JL. Aesthetic plastic surgery. Philadelphia: Elsevier Saunders, 2009. p. 15-24. ISBN 978-0-7020-3168-7.

ESTETICA; CIRURGIA PLASTICA; FOTOGRAFIA CLINICA; FOTOGRAFIA DIGITAL

Primeira | Anterior | Próxima | Última